Peptide Based Gastrointestinal Disorders Therapeutics Market (2017 - 2027)
Peptide Based Gastrointestinal Disorders Therapeutics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022
Core Findings
FREE CustomizationInroduction
Pharmaceutical companies are increasingly collaborating with medical institutes and research centers in order to ramp up R&D pipelines of peptide drugs. This is expected to influence the growth of the global peptide based gastrointestinal disorders therapeutics market over the next couple of years.
Rising prevalence of metabolic diseases and gastrointestinal disorders pertaining to the digestive system is prompting medical practitioners to utilize new therapeutics including peptides. In the near future, application of peptides is also expected to increase in other therapeutic areas as well.
Moreover, technological advancement in peptide synthesis which include hybrid combination of liquid and solid synthesis and high-throughput approaches is expected to play a crucial role in development of more effective peptide based therapeutic drugs for treating gastrointestinal disorders.
Such developments in the peptide therapeutics is also giving new hope to patients seeking affordable and effect therapeutic treatments. In addition, manufacturers are actively focusing on improving peptide properties, such as half-life and stability to address the various unmet medical needs.
According to the latest report published by Fact.MR, the global peptide based gastrointestinal disorders therapeutics market is set to reflect a double-digit CAGR between 2017 and 2022, to surpass a valuation of US$ 600 Mn.
Peptide is a biologically, naturally or artificially constituted form of amino acid monomers. Peptides can be utilized for treating various gastrointestinal disorders that mostly effect parts of the digestive system such as the gastrointestinal tract, large intestine, small intestine, stomach, esophagus, and rectum.
Peptides are considered as an effective therapeutic agent for treating gastrointestinal diseases. Owing to their impressive preclinical results, an array of new peptide based gastrointestinal disorder therapeutics are expected to enter the market soon.
North America to Lead the Global Peptide Based Gastrointestinal Disorders Therapeutics Market
In terms of revenue, North America is expected to hold the dominant share of the global peptide based gastrointestinal disorders therapeutics market in 2017 and beyond. Factors such growing patient awareness and rapid adoption of peptide based therapeutics for treating various diseases are expected to support the growth of the market in the region.
During the forecast period, the market in the region is projected to surge at a robust CAGR of 13.9%.
On the basis of drugs, the linaclotide segment is expected to retain its dominant position over 2022. Currently, the segment accounts for more than two-third share of the market in terms of revenue.
Towards the end of the forecast period, the linaclotide segment is estimated to reach a market valuation in excess of US$ 466 Mn.
Competition Tracking
- Shire plc
- Ironwood Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- Allergan plc
- Accredo Health Group, Inc.,
are the key market players profiled in the Fact.MR’s report. A majority of these companies are channelizing investment in further expansion of their product portfolio.
This, in turn, is anticipated to result in introduction of more efficacious peptide based therapeutic drugs for curing gastrointestinal ailments.
Market Taxonomy
-
By Drug :
- Teduglutide
- Linaclotide
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)
Table of Content
- 1. Global Market - Executive Summary
- 2. Global Market Overview
- 3. Global Market Analysis and Forecast By Drug
- 3.1. Teduglutide
- 3.2. Linaclotide
- 4. Global Market Analysis and Forecast By Distribution Channel
- 4.1. Hospital Pharmacies
- 4.2. Retail Pharmacies
- 4.3. Online Pharmacies
- 5. Global Market Analysis and Forecast By Region
- 5.1. North America
- 5.2. Latin America
- 5.3. Europe
- 5.4. Japan
- 5.5. APEJ
- 5.6. MEA
- 6. North America Market Analysis and Forecast, By Country, 2012 to 2022
- 7. Latin America Market Analysis and Forecast, By Country, 2012 to 2022
- 8. Europe Market Analysis and Forecast, By Country, 2012 to 2022
- 9. Japan Market Analysis and Forecast, By Country, 2012 to 2022
- 10. APEJ Market Analysis and Forecast, By Country, 2012 to 2022
- 11. MEA Market Analysis and Forecast, By Country, 2012 to 2022
- 12. Global Market Competition Landscape and Company Profile
- 12.1. Shire plc
- 12.2. Ironwood Pharmaceuticals, Inc
- 12.3. Astellas Pharma Inc
- 12.4. Allergan plc
- 12.5. Accredo Health Group, Inc
- 13. Research Methodology
- 14. Secondary and Primary Sources
- 15. Assumptions and Acronyms
- 16. Disclaimer
List Of Table
TABLE 01: Global Market Value (US$ Mn), 2012 to 2016
TABLE 02: Global Market Value (US$ Mn), 2017 to 2022
TABLE 3 :Global Market Value (US$ Mn) and Y-o-Y, 2015 to 2022
TABLE 04: Global Teduglutide Segment Value (US$ Mn), By Region 2012 to 2016
TABLE 05: Global Teduglutide Segment Value (US$ Mn), By Region 2017 to 2022
TABLE 06: Global Teduglutide Segment Market Share, By Region 2012 to 2016
TABLE 07: Global Teduglutide Segment Market Share, By Region 2017 to 2022
TABLE 08: Global Teduglutide Segment Y-o-Y, By Region 2015 to 2022
TABLE 09: Global Linaclotide Segment Value (US$ Mn), By Region 2012 to 2016
TABLE 10: Global Linaclotide Segment Value (US$ Mn), By Region 2017 to 2022
TABLE 11: Global Linaclotide Segment Market Share, By Region 2012 to 2016
TABLE 12: Global Linaclotide Segment Market Share, By Region 2017 to 2022
TABLE 13: Global Linaclotide Segment Y-o-Y, By Region 2015 to 2022
TABLE 14: Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2012 to 2016
TABLE 15: Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2017 to 2022
TABLE 16: Global Hospital Pharmacies Segment Market Share, By Region 2012 to 2016
TABLE 17: Global Hospital Pharmacies Segment Market Share, By Region 2017 to 2022
TABLE 18: Global Hospital Pharmacies Segment Y-o-Y, By Region 2015 to 2022
TABLE 19: Global Retail Pharmacies Segment Value (US$ Mn), By Region 2012 to 2016
TABLE 20: Global Retail Pharmacies Segment Value (US$ Mn), By Region 2017 to 2022
TABLE 21: Global Retail Pharmacies Segment Market Share, By Region 2012 to 2016
TABLE 22: Global Retail Pharmacies Segment Market Share, By Region 2017 to 2022
TABLE 23: Global Retail Pharmacies Segment Y-o-Y, By Region 2015 to 2022
TABLE 24: Global Online Pharmacies Segment Value (US$ Mn), By Region 2012 to 2016
TABLE 25: Global Online Pharmacies Segment Value (US$ Mn), By Region 2017 to 2022
TABLE 26: Global Online Pharmacies Segment Market Share, By Region 2012 to 2016
TABLE 27: Global Online Pharmacies Segment Market Share, By Region 2017 to 2022
TABLE 28: Global Online Pharmacies Segment Y-o-Y, By Region 2015 to 2022
TABLE 29: North America Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 30: North America Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 31: North America Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 32: North America Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 33: Latin America Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 34: Latin America Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 35: Latin America Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 36: Latin America Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 37: Europe Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 38: Europe Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 39: Europe Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 40: Europe Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 41: Japan Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 42: Japan Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 43: Japan Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 44: Japan Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 45: APEJ Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 46: APEJ Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 47: APEJ Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 48: APEJ Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 49: MEA Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 50: MEA Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 51: MEA Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 52: MEA Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 53: US Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 54: US Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 55: US Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 56: US Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 57: Canada Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 58: Canada Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 59: Canada Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 60: Canada Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 61: Brazil Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 62: Brazil Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 63: Brazil Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 64: Brazil Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 65: Mexico Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 66: Mexico Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 67: Mexico Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 68: Mexico Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 69: Argentina Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 70: Argentina Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 71: Argentina Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 72: Argentina Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 73: Germany Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 74: Germany Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 75: Germany Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 76: Germany Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 77: UK Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 78: UK Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 79: UK Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 80: UK Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 81: France Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 82: France Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 83: France Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 84: France Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 85: Spain Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 86: Spain Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 87: Spain Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 88: Spain Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 89: Italy Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 90: Italy Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 91: Italy Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 92: Italy Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 93: Nordic Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 94: Nordic Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 95: Nordic Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 96: Nordic Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 97: Japan Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 98: Japan Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 99: Japan Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 100: Japan Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 101: China Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 102: China Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 103: China Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 104: China Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 105: India Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 106: India Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 107: India Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 108: India Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 109: Malaysia Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 110: Malaysia Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 111: Malaysia Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 112: Malaysia Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 113: Thailand Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 114: Thailand Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 115: Thailand Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 116: Thailand Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 117: Singapore Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 118: Singapore Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 119: Singapore Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 120: Singapore Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 121: Australia Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 122: Australia Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 123: Australia Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 124: Australia Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 125: GCC Countries Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 126: GCC Countries Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 127: GCC Countries Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 128: GCC Countries Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 129: South Africa Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 130: South Africa Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 131: South Africa Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 132: South Africa Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 133: Nigeria Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 134: Nigeria Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 135: Nigeria Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 136: Nigeria Market Value (US$ Mn), By Distribution Channel 2017 to 2022
TABLE 137: Israel Market Value (US$ Mn), By Drug 2012 to 2016
TABLE 138: Israel Market Value (US$ Mn), By Drug 2017 to 2022
TABLE 139: Israel Market Value (US$ Mn), By Distribution Channel 2012 to 2016
TABLE 140: Israel Market Value (US$ Mn), By Distribution Channel 2017 to 2022
List Of Figures
FIG. 01: Global Market Value (US$ Mn), 2012 to 2016
FIG. 02: Global Market Value (US$ Mn) Forecast, 2017 to 2022
FIG. 03: Global Market Value (US$ Mn) and Y-o-Y, 2015 to 2022
FIG. 04: Global Teduglutide Segment Market Value (US$ Mn) By Region, 2012 to 2016
FIG. 05: Global Teduglutide Segment Market Value (US$ Mn) By Region, 2017 to 2022
FIG. 06: Global Teduglutide Segment Y-o-Y Growth Rate, By Region, 2015 to 2022
FIG. 07: Global Linaclotide Segment Market Value (US$ Mn) By Region, 2012 to 2016
FIG. 08: Global Linaclotide Segment Market Value (US$ Mn) By Region, 2017 to 2022
FIG. 09: Global Linaclotide Segment Y-o-Y Growth Rate, By Region, 2015 to 2022
FIG. 10: Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2012 to 2016
FIG. 11: Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2017 to 2022
FIG. 12: Global Hospital Pharmacies Segment Y-o-Y Growth Rate, By Region, 2015 to 2022
FIG. 13: Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2012 to 2016
FIG. 14: Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2017 to 2022
FIG. 15: Global Retail Pharmacies Segment Y-o-Y Growth Rate, By Region, 2015 to 2022
FIG. 16: Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2012 to 2016
FIG. 17: Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2017 to 2022
FIG. 18: Global Online Pharmacies Segment Y-o-Y Growth Rate, By Region, 2015 to 2022
FIG. 19: North America Market Value (US$ Mn), By Drug 2012 to 2016
FIG. 20: North America Market Value (US$ Mn), By Drug 2017 to 2022
FIG. 21: North America Market Value (US$ Mn), By Distribution Channel 2012 to 2016
FIG. 22: North America Market Value (US$ Mn), By Distribution Channel 2017 to 2022
FIG. 23: Latin America Market Value (US$ Mn), By Drug 2012 to 2016
FIG. 24: Latin America Market Value (US$ Mn), By Drug 2017 to 2022
FIG. 25: Latin America Market Value (US$ Mn), By Distribution Channel 2012 to 2016
FIG. 26: Latin America Market Value (US$ Mn), By Distribution Channel 2017 to 2022
FIG. 27: Europe Market Value (US$ Mn), By Drug 2012 to 2016
FIG. 28: Europe Market Value (US$ Mn), By Drug 2017 to 2022
FIG. 29: Europe Market Value (US$ Mn), By Distribution Channel 2012 to 2016
FIG. 30: Europe Market Value (US$ Mn), By Distribution Channel 2017 to 2022
FIG. 31: Japan Market Value (US$ Mn), By Drug 2012 to 2016
FIG. 32: Japan Market Value (US$ Mn), By Drug 2017 to 2022
FIG. 33: Japan Market Value (US$ Mn), By Distribution Channel 2012 to 2016
FIG. 34: Japan Market Value (US$ Mn), By Distribution Channel 2017 to 2022
FIG. 35: APEJ Market Value (US$ Mn), By Drug 2012 to 2016
FIG. 36: APEJ Market Value (US$ Mn), By Drug 2017 to 2022
FIG. 37: APEJ Market Value (US$ Mn), By Distribution Channel 2012 to 2016
FIG. 38: APEJ Market Value (US$ Mn), By Distribution Channel 2017 to 2022
FIG. 39: MEA Market Value (US$ Mn), By Drug 2012 to 2016
FIG. 40: MEA Market Value (US$ Mn), By Drug 2017 to 2022
FIG. 41: MEA Market Value (US$ Mn), By Distribution Channel 2012 to 2016
FIG. 42: MEA Market Value (US$ Mn), By Distribution Channel 2017 to 2022
- FAQs -
What is the growth prospect for the Peptide-based gastrointestinal disorders therapeutics market in North America by 2022?
With a CAGR of 13.9%, this market is showing robust prospects until 2022.
Which region is dominating the peptide-based gastrointestinal disorders therapeutics market?
North America is dominating this market during the forecast period of 2017-2022.
What is driving the demand for the peptide-based gastrointestinal disorders therapeutics market?
Rising prevalence of metabolic diseases and gastrointestinal disorders is driving demand for this market.
Related Reports
Peptide Based Gastrointestinal Disorders Therapeutics Market